Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition(s):Neuroendocrine TumorsLast Updated:September 14, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Neuroendocrine TumorsLast Updated:September 14, 2023Active, not recruiting
Condition(s):Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine TumorLast Updated:April 29, 2014Completed
Condition(s):Neuroendocrine TumorsLast Updated:March 5, 2024Recruiting
Condition(s):Neuroendocrine TumorsLast Updated:January 19, 2024Completed
Condition(s):Neuroendocrine TumorsLast Updated:November 21, 2018Unknown status
Condition(s):Neuroendocrine TumorsLast Updated:May 19, 2022Withdrawn
Condition(s):Neuroendocrine Tumors; Pancreatic Neuroendocrine TumorsLast Updated:April 14, 2022Completed
Condition(s):Pancreatic Neuroendocrine TumorLast Updated:October 22, 2019Unknown status
Condition(s):VHL Pancreatic Neuroendocrine Tumors; Von Hippel-Lindau Disease; Neuroendocrine TumorsLast Updated:March 13, 2024Recruiting
Condition(s):Neuroendocrine TumorsLast Updated:November 8, 2016No longer available
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.